In a report released today, Jason Kolbert from H.C. Wainwright maintained a Hold rating on IsoRay (ISR), with a price target of $1. The company’s shares opened today at $0.43.
Kolbert wrote:
“Our therapeutic models are patient-based, reflecting our assumptions for the market size, share penetration rates, and pricing. These metrics then flow into our valuation model. For IsoRay, we use a 15% discount rate as the company’s product (Cs-131 seeds) are approved for use in multiple indications.”
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.7% and a 33.0% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
IsoRay has an analyst consensus of Hold, with a price target consensus of $1, implying a 132.6% upside from current levels. In a report issued on November 9, Maxim Group also downgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
Based on IsoRay’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.51 million. In comparison, last year the company had a GAAP net loss of $1.55 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors.
